Dizocilpine-induced neuropathological changes in rat retrosplenial cortex are reversed by subsequent clozapine treatment

Life Sciences

Volumn 66, Issue 12, 2000, Pages 1071-1078

  Hashimoto, Kenji ^a   Fujimura, Masatake ^a   Yamagami, Keiji ^a  

^a Yoshitomi Pharmaceutical Industries Ltd   (Japan)

Author keywords

Clozapine; Dizocilpine; Neurotoxicity; NMDA receptor antagonist; Retrosplenial cortex

Indexed keywords

CLOZAPINE; DIZOCILPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; CHRONOTHERAPY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; RAT; TREATMENT OUTCOME;

ANIMALS; ANTIPSYCHOTIC AGENTS; CEREBRAL CORTEX; CLOZAPINE; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; LIMBIC SYSTEM; NERVOUS SYSTEM DISEASES; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; VACUOLES;

EID: 0034635606     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(00)00410-0     Document Type: Article

References (36)

1. 1. E.D. Luby, B.D. Cohen, G. Rosenbaum, J.S. Gottlieb and R. Kelley, Arch. Neurol. Psychiatry 81 363-369 (1959).
2. 2. J.H. Krystal, L.P. Karper, J.P. Seibyl, G.K. Freeman, R. Delaney, J.D. Bremner, G.R. Heninger, M.B. Bowers, D.S. Charney, Arch. Gen Psychiatry 51 199-214 (1994).
3. 3. E.D. Luby, J.S. Gottlieb, B.D. Cohen, G. Rosenbaum and E.F. Domino, Am. J. Psychiatry 119 61-67 (1962).
4. 4. D.C. Javitt and S.R. Zukin, Am. J. Psychiatry 148 1301-1308 (1991).
5. 5. G. Ellison, Brain Res. Rev., 20 250-267 (1995).
6. 6. J.W. Olney and N.B. Farber, Arch. Gen. Psychiatry 52 998-1007 (1995).
7. 7. J.T. Coyle, Harv. Rev. Psychiatry 3 241-253 (1996).
8. 8. C.A. Tamminga, Crit. Rev. Neurobiol., 12 21-36 (1998).
9. 9. J.W. Olney, J. Labruyere and M.T. Price, Science 244 1360-1362 (1989).
10. 10. A.S. Fix, G.G. Long, D.F. Wozniak and J.W. Olney, Drug Dev. Res., 32 147-152 (1994).
11. 11. C.R. Ashby and R.Y. Wang, Synapse 24 349-394 (1996).
12. 12. R.Y. Wang and X. Liang, Neuropsychopharmacol. 19 74-85 (1998).
13. 13. V.L. Arvanov and R.Y. Wang, J. Pharmacol. Exp. Ther. 289 1000-1006 (1999).
14. 14. Y. Minabe, K. Watanabe, K. Nishimura and C.R. Ashby, Synapse 29 272-278 (1998).
15. 15. N.B. Farber, M.T. Price, J. Labruyere, J. Nemnich, H.S. Peter, D.F. Wozniak and J.W. Olney, Biol. Psychiatry 34 119-121 (1993).
16. 16. N.B. Farber, J. Foster, N.L. Duhan and J.W. Olney, Schizophrenia Res. 21 33-37 (1996).
17. 17. G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates. Academic Press, San Diego, CA, USA, (1997).
18. 18. N.B. Farber, J.W. Newcomer and J.W. Olney, Prog. Brain Res. 116 421-437 (1998).
19. 19. J. McCulloch and L.L. Iversen, Neurochem. Res. 16 951-963 (1991).
20. 20. P. Gass, T. Herdegen, R. Bravo and M. Kiessling, Neurosci. 53 749-758 (1993).
21. 21. I.R. Brown, Heat Shock Proteins in the Nervous System, J. Mayer and I. Brown (Eds), 31-53 (1994).
22. 22. W.J. Welch, Physiol. Rev. 72 1063-1081 (1992).
23. 23. K. Hashimoto, S. Tomitaka, Y. Bi, N. Narita, Y. Minabe and M. Iyo, Eur. J. Neurosci., 9 1891-1901 (1997).
24. 24. K. Hashimoto, S. Tomitaka, N. Narita, Y. Minabe, M. Iyo and S. Fukui, Addiction Biol. 1 61-70 (1996).
25. 25. F.R. Sharp, P. Jasper, J. Hall, L. Noble and S.M. Sagar, Ann. Neurol., 30 801-809 (1991).
26. 26. F.R. Sharp, M. Butman, J. Koistinaho, K. Aardalen, R. Nakki, S.M. Massa, R. Swanson and S.M. Sagar, Neurosci. 62 1079-1092 (1994).
27. 27. S. Tomitaka, K. Hashimoto, N. Narita, A. Sakamoto, Y. Minabe and A. Tamura, Brain Res. 740 1-5 (1996).
28. 28. E. Castren, M.P. Berzaghi, D. Lindholm and H. Thoenen, Exp. Neurol. 122 244-252 (1993).
29. 29. K. Hashimoto, Y. Minabe and M. Iyo, Addiction Biol. 3 79-83 (1998).
30. 30. Jevtovic-Todorovic, V., J.W. Newcomer, J.W. Olney and N.B. Farber, Soc. Neurosci. Abstr. 25 1817 (Abstr. No. 727.2) (1999).
31. 31. T.D. Corso, M.A. Sesma, T.I. Tenkova, T.C. Der, D.F. Wozniak, N.B. Farber and J.W. Olney, Brain Res. 752 1-14 (1997).
32. 32. P. Michal, M. Lysikova, E.E. El-Fakahany and S. Tucek, Eur. J. Pharmacol. 376 119-125 (1999).
33. 33. X.P. Zeng, F. Le and E. Richelson, Eur. J. Pharmacol. 321 349-354 (1997).
34. 34. M.C. Olianis, C. Maullu, C. and P. Onali, Neuropsychopharmacol. 20 263-270 (1999).
35. 35. C.R. Ashby Jr. and R.Y. Wang, Brain Res. 506 346-348 (1990).
36. 36. J.E. Leysen, W. Gommeren and A. Schotte, Serotonin in Antipsychotic Treatment - Mechanisms and Clinical Practice, J.M. Kane, H.-J. Moller and F. Awouters (eds), 51-75 (1996)